Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials

Journal of Diabetes and its Complications

Volumn 27, Issue 3, 2013, Pages 274-279

  Del Prato, Stefano ^a   Taskinen, Marja Riitta ^b   Owens, David R ^c   Von Eynatten, Maximilian ^d   Emser, Angela ^d   Gong, Yan ^d   Chiavetta, Silvia ^e   Patel, Sanjay ^f   Woerle, Hans Juergen ^d  

^a UNIVERSITY OF PISA   (Italy)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c CARDIFF UNIVERSITY   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Boehringer Ingelheim Italia SpA   (Italy)

^f BOEHRINGER INGELHEIM LTD   (United Kingdom)

Author keywords

Combination therapy; DPP 4 inhibitor; Linagliptin; Poor glycemic control; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; KIDNEY; MALE; METFORMIN; MIDDLE AGED; PURINES; QUINAZOLINES; SULFONYLUREA COMPOUNDS;

EID: 84876931934     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2012.11.008     Document Type: Article

References (19)

1. P. Aschner, J. Chan, D.R. Owens, S. Picard, E. Wang, and M.P. Dain Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial Lancet 379 2012 2262 2269
2. P. Aschner, H.L. Katzeff, H. Guo, S. Sunga, D. Williams-Herman, and K.D. Kaufman Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes Diabetes, Obesity & Metabolism 12 2010 252 261
3. Z.T. Bloomgarden, R. Dodis, C.M. Viscoli, E.S. Holmboe, and S.E. Inzucchi Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis Diabetes Care 29 2006 2137 2139
4. R.A. DeFronzo, A.H. Stonehouse, J. Han, and M.E. Wintle Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials Diabetic Medicine 27 2010 309 317
5. S. Del Prato, A.H. Barnett, H. Huisman, D. Neubacher, H.J. Woerle, and K.A. Dugi Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial Diabetes, Obesity & Metabolism 13 2011 258 267
6. R. Gomis, R.M. Espadero, R. Jones, H.J. Woerle, and K.A. Dugi Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo controlled study Diabetes, Obesity & Metabolism 13 2011 653 661
7. M. Goodman, H. Thurston, and J. Penman Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy Hormone and Metabolic Research 41 2009 368 373
8. P. Hollander, J. Li, E. Allen, and R. Chen Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone Journal of Clinical Endocrinology and Metabolism 94 2009 4810 4819
9. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, and M. Nauck Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
10. Y. Iwamoto, A. Kashiwagi, N. Yamada, S. Terao, N. Mimori, and M. Suzuki Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study Diabetes, Obesity & Metabolism 12 2010 700 708
11. H. Maeda, A. Kubota, Y. Tanaka, Y. Terauchi, and I. Matsuba The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes Diabetes Research and Clinical Practice 95 2012 e20 22
12. D.R. Owens, R. Swallow, K.A. Dugi, and H.J. Woerle Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study Diabetic Medicine 28 2011 1352 1361
13. I. Raz, Y. Chen, M. Wu, S. Hussain, K.D. Kaufman, and J.M. Amatruda Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes Current Medical Research and Opinion 24 2008 537 550
14. B. Richter, E. Bandeira-Echtler, K. Bergerhoff, and C.L. Lerch Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database of Systematic Reviews 2008 CD006739
15. A.J. Scheen Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions Clinical Pharmacokinetics 49 2010 573 588
16. G. Schernthaner, A.H. Barnett, A. Emser, S. Patel, J. Troost, and H.J. Woerle Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus Diabetes, Obesity & Metabolism 14 2012 470 478
17. M.R. Taskinen, J. Rosenstock, I. Tamminen, R. Kubiak, S. Patel, and K.A. Dugi Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study Diabetes, Obesity & Metabolism 13 2011 65 74
18. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl- quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors Journal of Pharmacology and Experimental Therapeutics 325 2008 175 182
19. Workgroup on Hypoglycemia, American Diabetes Association Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 28 2005 1245 1249